PD-1/PD-L1 Inhibitors versus Chemotherapy for Previously Treated Advanced Gastroesophageal Cancer: A Meta-Analysis of Randomized Controlled Trials

Table 1

Search terms and search strategy based on PICOS structure.

Population	Intervention	Comparison	Outcomes	Study design	Combining search terms
Patients with advanced gastroesophageal cancer who progressed after the failure of one or more chemotherapy regimens	PD-1/PD-L1 inhibitor monotherapy	Chemotherapy	ORR, PFS, OS, TRAEs	Randomized controlled trial	Column 1 AND Column 2 AND Column 3
“Esophageal OR gastric OR gastroesophageal junction” AND “cancer OR carcinoma OR neoplasm OR tumor OR adenocarcinoma”	PD-1 OR PD-L1 OR immune checkpoint inhibitor OR immunotherapy OR pembrolizumab OR nivolumab OR avelumab OR atezolizumab OR durvalumab OR camrelizumab OR SHR-1210 OR toripalimab OR sintilimab OR tislelizumab			Study OR trial OR clinical trial OR randomized clinical trial OR randomized controlled trial OR randomized controlled clinical trial